|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cole SW and Sood AK: Molecular pathways:
Beta-adrenergic signaling in cancer. Clin Cancer Res. 18:1201–1206.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maccari S, Buoncervello M, Rampin A, Spada
M, Macchia D, Giordani L, Stati T, Bearzi C, Catalano L, Rizzi R,
et al: Biphasic effects of propranolol on tumour growth in B16F10
melanoma-bearing mice. Br J Pharmacol. 174:139–149. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montoya A, Amaya CN, Belmont A, Diab N,
Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S,
et al: Use of non-selective beta-blockers is associated with
decreased tumor proliferative indices in early stage breast cancer.
Oncotarget. 8:6446–6460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson JM, Lorimer E, Tyburski MD and
Williams CL: β-Adrenergic receptors suppress Rap1B prenylation and
promote the metastatic phenotype in breast cancer cells. Cancer
Biol Ther. 16:1364–1374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei WJ, Shen CT, Song HJ, Qiu ZL and Luo
QY: Propranolol sensitizes thyroid cancer cells to cytotoxic effect
of vemurafenib. Oncol Rep. 36:1576–1584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorski L, Melamed R, Matzner P, Lavon H,
Shaashua L, Rosenne E and Ben-Eliyahu S: Reducing liver metastases
of colon cancer in the context of extensive and minor surgeries
through β-adrenoceptors blockade and COX2 inhibition. Brain Behav
Immun. 58:91–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Partecke LI, Speerforck S, Kading A,
Seubert F, Kuhn S, Lorenz E, Schwandke S, Sendler M, Kessler W,
Trung DN, et al: Chronic stress increases experimental pancreatic
cancer growth, reduces survival and can be antagonised by
beta-adrenergic receptor blockade. Pancreatology. 16:423–433. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cardwell CR, Pottegard A, Vaes E, Garmo H,
Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvanathan K,
Cronin-Fenton D, et al: Propranolol and survival from breast
cancer: A pooled analysis of European breast cancer cohorts. Breast
Cancer Res. 18:1192016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoeger PH, Harper JI, Baselga E, Bonnet D,
Boon LM, Ciofi Degli Atti M, El Hachem M, Oranje AP, Rubin AT,
Weibel L and Leaute-Labreze C: Treatment of infantile haemangiomas:
Recommendations of a European expert group. Eur J Pediatr.
174:855–865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garcia-Tsao G, Sanyal AJ, Grace ND and
Carey W: Practice Guidelines Committee of the American Association
for the Study of Liver D, Practice Parameters Committee of the
American College of G. Prevention and management of
gastroesophageal varices and variceal hemorrhage in cirrhosis.
Hepatology. 46:922–938. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rico M, Baglioni M, Bondarenko M, Laluce
NC, Rozados V, Andre N, Carre M, Scharovsky OG and Menacho Marquez
M: Metformin and propranolol combination prevents cancer
progression and metastasis in different breast cancer models.
Oncotarget. 8:2874–2889. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hwa YL, Shi Q, Kumar SK, Lacy MQ, Gertz
MA, Kapoor P, Buadi FK, Leung N, Dingli D, Go RS, et al:
Beta-blockers improve survival outcomes in patients with multiple
myeloma: A retrospective evaluation. Am J Hematol. 92:50–55. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang PY, Huang WY, Lin CL, Huang TC, Wu
YY, Chen JH and Kao CH: Propranolol reduces cancer risk: A
population-based cohort study. Medicine (Baltimore). 94:e10972015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pantziarka P, Bouche G, Sukhatme V, Meheus
L, Rooman I and Sukhatme VP: Repurposing drugs in oncology
(ReDO)-propranolol as an anti-cancer agent. Ecancermedicalscience.
10:6802016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thiele M, Wiest R, Gluud LL, Albillos A
and Krag A: Can non-selective beta-blockers prevent hepatocellular
carcinoma in patients with cirrhosis? Med Hypotheses. 81:871–874.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herrera I, Pascual S, Zapater P, Carnicer
F, Bellot P and María Palazón J: The use of β-blockers is
associated with a lower risk of developing hepatocellular carcinoma
in patients with cirrhosis. Eur J Gastroenterol Hepatol.
28:1194–1197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu HH, Liu J, Lin YL, Luo WS, Chu YJ,
Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, et al: The rs2296651
(S267F) variant on NTCP (SLC10A1) is inversely associated with
chronic hepatitis B and progression to cirrhosis and hepatocellular
carcinoma in patients with chronic hepatitis B. Gut. 65:1514–1521.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cavuoto J: Neurotech report.
Neuromodulation. 14:1032011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee HS, Chung YH and Kim CY: Specificities
of serum alpha-fetoprotein in HBsAg+ and HBsAg-patients in the
diagnosis of hepatocellular carcinoma. Hepatology. 14:68–72. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lopez-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kassahun WT, Guenl B, Ungemach FR, Jonas S
and Abraham G: Expression and functional coupling of liver
β2-adrenoceptors in the human hepatocellular carcinoma.
Pharmacology. 89:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bevilacqua M, Norbiato G, Chebat E, Baldi
G, Bertora P, Regalia E, Colella G, Gennari L and Vago T: Changes
in alpha-1 and beta-2 adrenoceptor density in human hepatocellular
carcinoma. Cancer. 67:2543–2551. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iseri OD, Sahin FI, Terzi YK, Yurtcu E,
Erdem SR and Sarialioglu F: Beta-Adrenoreceptor antagonists reduce
cancer cell proliferation, invasion and migration. Pharm Biol.
52:1374–1381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang ZF, Feng XS, Chen H, Duan ZJ, Wang
LX, Yang D, Liu PX, Zhang QP, Jin YL, Sun ZG and Liu H: Prognostic
significance of synergistic hexokinase-2 and beta2-adrenergic
receptor expression in human hepatocelluar carcinoma after curative
resection. BMC Gastroenterol. 16:572016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu FQ, Fang T, Yu LX, Lv GS, Lv HW, Liang
D, Li T, Wang CZ, Tan YX, Ding J, et al: ADRB2 signaling promotes
HCC progression and sorafenib resistance by inhibiting autophagic
degradation of HIF1α. J Hepatol. 65:314–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou C, Chen X, Zeng W, Peng C, Huang G,
Li X, Ouyang Z, Luo Y, Xu X, Xu B, et al: Propranolol induced
G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK
pathway. Oncotarget. 7:68314–68327. 2016.PubMed/NCBI
|
